Targeting fibrosis, mechanisms and cilinical trials.
Zhao M, Wang L, Wang M, Zhou S, Lu Y, Cui H, Racanelli AC, Zhang L, Ye T, Ding B, Zhang B, Yang J, Yao Y. · 2022
Read Targeting fibrosis, mechanisms and cilinical trials. by Zhao M, Wang L, Wang M, Zhou S, Lu Y, Cui H, Racanelli AC, Zhang L, Ye T, Ding B, Zhang B, Yang J, Yao Y. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9247101.txt.
Description
Zhao and co-authors review fibrosis, its mechanisms, and drugs now in clinical trials. Fibrosis means excess matrix deposits after a faulty repair response. It can strike the liver, kidney, heart, and lung. Diseases like liver cirrhosis and idiopathic pulmonary fibrosis carry a heavy global burden.
A key driver is the lasting activation of myofibroblasts, the cells that lay down matrix. Signals like transforming growth factor keep them switched on. The review first covers causes and spread for several organs. It then maps the abnormal cells and their interactions. Aberrant pathways that control matrix cross-linking, metabolism, and inflammation are detailed. Drugs aimed at those targets are assessed trial by trial.
Catalog record
| CREATOR | Zhao M, Wang L, Wang M, Zhou S, Lu Y, Cui H, Racanelli AC, Zhang L, Ye T, Ding B, Zhang B, Yang J, Yao Y. |
|---|---|
| YEAR | 2022 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 135 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |